UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if patients with high risk disease because of age or
kidney status can be treated more safely with a drug called Busulfex® followed by autologous
transplant compared to treatment with the standard drug called melphalan, which has been
shown to be quite difficult to tolerate in patients with poor kidney function and patients
over the age of 65 when given in high doses.